Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 3/2017

01-03-2017 | Review Article

Aspirin-exacerbated respiratory disease and current treatment modalities

Authors: Emine Güven Sakalar, Nuray Bayar Muluk, Murat Kar, Cemal Cingi

Published in: European Archives of Oto-Rhino-Laryngology | Issue 3/2017

Login to get access

Abstract

Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs. AERD affects 0.3–0.9 % of the general population. AERD generally occurs due to abnormalities in mediators and expression of arachidonic acid biosynthesis. Local IgE responses to staphylococcal enterotoxins may also be responsible for eosinophilic activation in the nasal polyp tissues of AERD patients. Clinical features of AERD include the onset of nasal congestion with anosmia, progressing to chronic pansinusitis and nasal polyps that regrow rapidly after surgery. Aspirin desensitization, Leukotriene-modifying agents, biologic agents, management of asthma, chronic rhinosinusitis, and nasal polyposis are recommended as treatment modalities. Immunotherapy is prescribed only to those AERD patients who experience clear seasonal or perennial allergy symptoms in addition to the symptoms attributable to chronic nasal polyposis. There are also investigational and dietary therapies. In this review, the important aspects of AERD will be presented, along with a literature survey.
Literature
1.
2.
3.
4.
Berges-Gimeno MP, Simon RA, Stevenson DD (2002) The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89:474–478CrossRefPubMed
5.
Fahrenholz JM (2003) Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 24(2):113–124CrossRefPubMed
6.
Szczeklik A, Nizankowska-Mogilnicka E, Sanak M (2009) Hypersensitivity to aspirin and non-steroidal anti-inflammatory drugs. In: Adkinson NF Jr, Bochner BS, Busse WW, Holgate ST, Lemanske RF Jr, Simons FER (eds) Middleton’s allergy: principles and practice, 7th edn. Mosby, New York, pp 1227–1240CrossRef
7.
Stevenson DD (2009) Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 9:155–163CrossRefPubMed
8.
Mullol J, Picado C (2013) Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin N Am 33:163–176CrossRef
9.
Jenkins C, Costello J, Hodge L (2004) Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328(7437):434CrossRefPubMedPubMedCentral
10.
McDonald JR, Mathison DA, Stevenson DD (1972) Aspirin intolerance in asthma. Detection by oral challenge. J Allergy Clin Immunol 50(4):198–207CrossRefPubMed
11.
Weber RW, Hoffman M, Raine DA Jr, Nelson HS (1979) Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 64(1):32–37CrossRefPubMed
12.
Delaney JC (1976) The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clin Allergy 6(2):177–181CrossRefPubMed
13.
Berges-Gimeno MP, Simon RA, Stevenson DD (2002) The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89(5):474–478CrossRefPubMed
14.
Rajan JP, Wineinger NE, Stevenson DD, White AA (2015) Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 135(3):676–681CrossRefPubMed
15.
Szczeklik A, Nizankowska E, Duplaga M (2000) Natural history of aspirin-induced asthma. AIANE Investigators. European network on aspirin-induced asthma. Eur Respir J 16:432–436CrossRefPubMed
16.
Hamad AM, Sutcliffe AM, Knox AJ (2004) Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 64(21):2417–2432CrossRefPubMed
17.
18.
Higashi N, Taniguchi M, Mita H, Kawagishi Y, Ishii T, Higashi A et al (2004) Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 113(2):277–283CrossRefPubMed
19.
Cai Y, Bjermer L, Halstensen TS (2003) Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am J Respir Cell Mol Biol 29(6):683–693CrossRefPubMed
20.
Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A et al (1998) Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101(4):834–846CrossRefPubMedPubMedCentral
21.
Nasser S, Christie PE, Pfister R, Sousa AR, Walls A, Schmitz-Schumann M et al (1996) Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 51(1):64–70CrossRefPubMedPubMedCentral
22.
Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J et al (1994) Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 94(6 Pt 1):1046–1056CrossRefPubMed
23.
Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C (2005) Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 115(6):1189–1196CrossRefPubMed
24.
Choi GS, Kim JH, Shin YS, Ye YM, Kim SH, Park HS (2013) Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin Exp Allergy 43(7):730–740CrossRefPubMed
25.
Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L (2013) Prominent role of IFN-[gamma] in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 132:856–865CrossRefPubMedPubMedCentral
26.
Suh Y, Yoon S, Sampson A, Kim HJ, Kim SH, Nahm DH et al (2004) Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma. Clin Exp Allergy 34(8):1270–1275CrossRefPubMed
27.
Pérez-Novo CA, Kowalski ML, Kuna P, Ptasinska A, Holtappels G, van Cauwenberge P et al (2004) Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship. Int Arch Allergy Immunol 133(3):255–260CrossRefPubMed
28.
Conley DB, Tripathi A, Seiberling KA, Schleimer RP, Suh LA, Harris K et al (2006) Superantigens and chronic rhinosinusitis: skewing of T-cell receptor V beta-distributions in polyp-derived CD4+ and CD8+ T cells. Am J Rhinol 20(5):534–539CrossRefPubMedPubMedCentral
29.
Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD (2008) Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 100(5):420–425CrossRefPubMed
30.
Stevenson DD, Szczeklik A (2006) Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118(4):773–786CrossRefPubMed
31.
Pfaar O, Klimek L (2006) Eicosanoids, aspirin-intolerance and the upper airways—current standards and recent improvements of the desensitization therapy. J Physiol Pharmacol 57(Suppl 12):5–13PubMed
32.
Milewski M, Mastalerz L, Nizankowska E, Szczeklik A (1998) Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 101(5):581–586CrossRefPubMed
33.
Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A (2000) Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 15:863–869CrossRefPubMed
34.
Parikh AA, Scadding GK (2005) Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 115(8):1385–1390CrossRefPubMed
35.
Graefe H, Roebke C, Schäfer D, Meyer JE (2012) Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination. J Allergy (Cairo) 2012:817910. doi:10.​1155/​2012/​817910
36.
Schäfer D, Maune S (2012) Pathogenic mechanisms and in vitro diagnosis of AERD. J Allergy (Cairo) 2012:789232
37.
De Weck AL, Sanz ML, Gamboa PM, Aberer W, Blanca M, Correia S et al (2009) Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J Investig Allergol Clin Immunol 5:355–369
38.
39.
Gaber F, Daham K, Higashi A, Higashi N, Gülich A, Delin I et al (2008) Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 63:1076–1082CrossRefPubMed
40.
Corey EJ, Niwa H, Falck JR, Mioskowski C, Arai Y, Marfat A (1980) Recent studies on the chemical synthesis of eicosanoids. Adv Prostaglandin Thromboxane Res 6:19–25PubMed
41.
Smith DL, Willis AL (1987) A suggested shorthand nomenclature for the eicosanoids. Lipids 22(12):983–986CrossRefPubMed
42.
Chilton FH, Fonteh AN, Surette ME, Triggiani M, Winkler JD (1996) Control of arachidonate levels within inflammatory cells. Biochim Biophys Acta 1299(1):1–15CrossRefPubMed
43.
Laneuville O, Breuer DK, Xu N, Huang ZH, Gage DA, Watson JT et al (1995) Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J Biol Chem 270(33):19330–19336CrossRefPubMed
44.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G et al (2007) EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62(10):1111–1118CrossRefPubMed
45.
Miller B, Mirakian R, Gane S, Larco J, Sannah AA, Darby Y et al (2013) Nasal lysine aspirin challenge in the diagnosis of aspirin: exacerbated respiratory disease: asthma and rhinitis. Clin Exp Allergy 43(8):874–880CrossRefPubMedPubMedCentral
46.
Hopkins C, Browne JP, Slack R, Lund V, Brown P (2007) The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg 137(4):555–561CrossRefPubMed
47.
Samter M, Beers RF Jr (1968) Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68(5):975–983CrossRefPubMed
48.
Widal MF, Abrami P, Lermeyez J (1922) Idiosyncratic anaphylaxis. Presse Med 30:189–192
49.
Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW (2005) Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 94(6):652–657CrossRefPubMed
50.
51.
Woessner KM, White AA (2014) Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 133(1):286.e1–9–287.e1–9CrossRef
52.
Kim YJ, Lim KH, Kim MY, Jo EJ, Lee SY, Lee SE et al (2014) Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Immunol Res 6(2):156–162CrossRefPubMed
53.
Christie PE, Smith CM, Lee TH (1991) The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 144(4):957–958CrossRefPubMed
54.
Nasser SM, Bell GS, Foster S, Spruce KE, MacMillan R, Williams AJ et al (1994) Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 49(8):749–756CrossRefPubMedPubMedCentral
55.
Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M et al (2002) Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165(1):9–14CrossRefPubMed
56.
Lee DK, Haggart K, Robb FM, Lipworth BJ (2004) Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 24(2):226–230CrossRefPubMed
57.
Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J et al (1993) The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148(6 Pt):1447–1451CrossRefPubMed
58.
Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M et al (1998) Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157(4 Pt 1):1187–1194CrossRefPubMed
59.
Ta V, White AA (2015) Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 3(5):711–718CrossRefPubMed
60.
Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD (1995) Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 96(4):480–485CrossRefPubMed
61.
Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH (2014) Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. J Allergy Clin Immunol 134(1):40–45CrossRefPubMed
62.
Steinke JW, Culp JA, Kropf E, Borish L (2009) Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 124(4):724–730CrossRefPubMed
63.
Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R (2010) The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 126(4):738–744CrossRefPubMed
64.
Lee JY, Simon RA, Stevenson DD (2007) Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 119:157–164CrossRefPubMed
65.
Berges-Gimeno MP, Simon RA, Stevenson DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111:180–186CrossRefPubMed
66.
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110.e1–116.e1CrossRef
67.
Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F et al (2011) Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal olyposis. J Allergy Clin Immunol 128(5):989.e1–8–995.e1–8CrossRef
68.
Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L (2015) Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy 8:105–114CrossRefPubMedPubMedCentral
69.
Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B et al (2012) Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 83(1):36–44CrossRefPubMed
70.
71.
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al (2012) EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50(1):1–12PubMed
72.
Ragab S, Parikh A, Darby YC, Scadding GK (2001) An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 31(9):1385–1391CrossRefPubMed
73.
Awad OG, Lee JH, Fasano MB, Graham SM (2008) Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? Laryngoscope 118(7):1282–1286CrossRefPubMed
74.
Morrissey DK, Bassiouni A, Psaltis AJ, Naidoo Y, Wormald PJ (2016) Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis. Int Forum Allergy Rhinol. doi:10.​1002/​alr.​21739 (Epub ahead of print)
75.
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al (2012) European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 23:3 p preceding table of contents: 1–298
76.
Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S (2003) Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 73:232–241CrossRefPubMed
77.
Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL et al (2012) Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 119:3790–3798CrossRefPubMedPubMedCentral
78.
Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y et al (2009) Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206:2543–2555CrossRefPubMedPubMedCentral
79.
Cummings HE, Liu T, Feng C, Laidlaw TM, Conley PB, Kanaoka Y et al (2013) Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol 191:5807–5810CrossRefPubMed
80.
Liu T, Laidlaw TM, Katz HR, Boyce JA (2013) Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci USA 110:16987–16992CrossRefPubMedPubMedCentral
81.
Kim SH, Choi JH, Park HS, Holloway JW, Lee SK, Park CS et al (2005) Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 35:585–590CrossRefPubMed
82.
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455–2466CrossRefPubMed
83.
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139CrossRefPubMed
84.
Chudwin DS, Strub M, Golden HE, Frey C, Richmond GW, Luskin AT (1986) Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis. Ann Allergy 57:133–134PubMed
85.
Park HS, Lim YS, Suh JE, Rhu NS, Cho DI, Kim JW (1991) Sodium salicylate sensitivity in an asthmatic patient with aspirin sensitivity. J Korean Med Sci 6:113–117CrossRefPubMedPubMedCentral
86.
Sommer DD, Hoffbauer S, Au M, Sowerby LJ, Gupta MK, Nayan S (2015) Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. Otolaryngol Head Neck Surg 152:42–47CrossRefPubMed
87.
Wood A, Baxter G, Thies F, Kyle J, Duthie G (2011) A systematic review of salicylates in food: estimated daily intake of a Scottish population. Mol Nutr Food Res suppl 1:S7–S14CrossRef
88.
Baxter GJ, Graham AB, Lawrence JR, Wiles D, Paterson JR (2001) Salicylic acid in soups prepared from organically and nonorganically grown vegetables. Eur J Nutr 40:289–292CrossRefPubMed
89.
Mitchell J, Skypala I (2013) Aspirin and salicylate in respiratory disease. Rhinology 51:195–205PubMed
Metadata
Title
Aspirin-exacerbated respiratory disease and current treatment modalities
Authors
Emine Güven Sakalar
Nuray Bayar Muluk
Murat Kar
Cemal Cingi
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 3/2017
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-016-4273-1

Other articles of this Issue 3/2017

European Archives of Oto-Rhino-Laryngology 3/2017 Go to the issue

Review Article

The clinical and radiological predictors of pulmonary hypertension in children with adenotonsillar hypertrophy

Head and Neck

Long-term results of a modified expansion sphincter pharyngoplasty for sleep-disordered breathing

Otology

Chronological changes in microbial profiles in external and middle ear diseases: a 20-year study in Korea

Head and Neck

An evaluation on novel application of cone-beam CT imaging with multi-volume technique in carotid body tumor

Otology

Feasibility of an implanted microphone for cochlear implant listening

Head and Neck

Thyroid autoimmunity: is really associated with papillary thyroid carcinoma?